4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. The company drew an initial $20 million at closing, with an additional $30 million available at its option through June 15, 2027, another $100 million upon achieving certain milestones, and the remaining $50 million subject to final lender approval. As of March 31, 2026, 4DMT held $458 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028. The non-dilutive financing is intended to support the Phase 3 development and pre-commercial planning of its lead gene therapy candidate 4D-150 for wet age-related macular degeneration and diabetic macular edema.
4D Molecular Therapeutics IncSecured up to $200M non-dilutive credit facility from Hercules Capital to fund Phase 3 and pre-commercial activities.
Hercules Capital, Inc.Hercules Capital provided the credit facility, generating fee income and interest revenue.
Advanced Micro Devices Inc